RASopathy: genes and variants
Explore variant evidence for RASopathy across 13 analyzed proteins (PTPN11, BRAF, RAF1, KRAS, SOS1 and 8 more). Linked ClinVar records include 212 pathogenic or likely pathogenic variants, 2,235 variants of uncertain significance and 257 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to RASopathy
PTPN11: Tyrosine-protein phosphatase non-receptor type 11
Its SHP2 phosphatase activity promotes RAS-MAPK signaling downstream of many receptor tyrosine kinases and cytokine receptors. Germline dysregulating variants cause Noonan-spectrum disorders, while somatic activating variants drive juvenile myelomonocytic leukemia and other cancers.
51 ClinVar pathogenic / likely pathogenic and 218 uncertain variants in PTPN11 have source records linked to RASopathy. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
36 ClinVar pathogenic / likely pathogenic and 285 uncertain variants in BRAF have source records linked to RASopathy. Association strength is not clinical gene validity.
RAF1: RAF proto-oncogene serine/threonine-protein kinase
It relays activated RAS signals to MEK and ERK and also participates in survival and developmental pathways. Germline activating variants cause Noonan syndrome and related RASopathies, while oncogenic activation contributes to selected cancers.
28 ClinVar pathogenic / likely pathogenic and 344 uncertain variants in RAF1 have source records linked to RASopathy. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
23 ClinVar pathogenic / likely pathogenic and 37 uncertain variants in KRAS have source records linked to RASopathy. Association strength is not clinical gene validity.
SOS1: Son of sevenless homolog 1
It activates RAS by exchanging GDP for GTP downstream of receptor tyrosine kinases. Germline activating variants are a common cause of Noonan syndrome, while excessive SOS1-RAS signaling can contribute to cancer.
22 ClinVar pathogenic / likely pathogenic and 537 uncertain variants in SOS1 have source records linked to RASopathy. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
14 ClinVar pathogenic / likely pathogenic and 129 uncertain variants in MAP2K1 have source records linked to RASopathy. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
9 ClinVar pathogenic / likely pathogenic and 261 uncertain variants in MAP2K2 have source records linked to RASopathy. Association strength is not clinical gene validity.
CBL: E3 ubiquitin-protein ligase CBL
It limits receptor-tyrosine-kinase signaling by ubiquitinating activated receptors and promoting their internalization and degradation. Germline or somatic pathogenic variants can prolong RAS-MAPK signaling and cause Noonan-like developmental disease or myeloid malignancy.
8 ClinVar pathogenic / likely pathogenic and 608 uncertain variants in CBL have source records linked to RASopathy. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
6 ClinVar pathogenic / likely pathogenic and 65 uncertain variants in NRAS have source records linked to RASopathy. Association strength is not clinical gene validity.
HRAS: GTPase HRas
Its GTP-bound state activates RAF-MEK-ERK and other pathways downstream of growth-factor receptors. Somatic activating variants drive several cancers, while germline activating variants cause Costello syndrome.
6 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in HRAS have source records linked to RASopathy. Association strength is not clinical gene validity.
RIT1: GTP-binding protein Rit1
It transmits growth and stress signals through RAS-MAPK and related pathways and is important in cardiovascular and nervous-system development. Germline activating variants cause Noonan syndrome, often with a high frequency of hypertrophic cardiomyopathy.
5 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in RIT1 have source records linked to RASopathy. Association strength is not clinical gene validity.
SOS2: Son of sevenless homolog 2
It activates RAS by catalyzing GDP-GTP exchange downstream of growth-factor receptors. Germline activating variants cause Noonan syndrome, generally through increased RAS-MAPK signaling.
3 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in SOS2 have source records linked to RASopathy. Association strength is not clinical gene validity.
SLC26A4: Pendrin
SLC26A4, known as pendrin, is an anion exchanger that transports chloride, iodide, and bicarbonate without directly using sodium. It supports ion balance in the inner ear and thyroid, and SLC26A4 variants cause Pendred syndrome and inherited deafness.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SLC26A4 have source records linked to RASopathy. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): DDC.
Where RASopathy variants cluster
- CBL Linker (positions 352–380): 5 of 8 ClinVar pathogenic / likely pathogenic variants, 19.5× more than its size predicts (a length-based count, not a validated hotspot).
- BRAF Protein kinase (positions 457–717): 25 of 34 ClinVar pathogenic / likely pathogenic variants, 2.2× more than its size predicts (a length-based count, not a validated hotspot).
- PTPN11 SH2 1 (positions 6–102): 21 of 47 ClinVar pathogenic / likely pathogenic variants, 2.7× more than its size predicts (a length-based count, not a validated hotspot).
- BRAF Phorbol-ester/DAG-type (positions 234–280): 8 of 34 ClinVar pathogenic / likely pathogenic variants, 3.8× more than its size predicts (a length-based count, not a validated hotspot).
- CBL RING-type (positions 381–420): 3 of 8 ClinVar pathogenic / likely pathogenic variants, 8.5× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to RASopathy
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| HRAS A59G | 59 | Pathogenic / likely pathogenic (★★★★) | |
| MAP2K2 Y134C | 134 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| MAP2K2 Y134H | 134 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Y279C | 279 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| HRAS A59L | 59 | Pathogenic / likely pathogenic (★★★) | |
| HRAS A59T | 59 | Pathogenic / likely pathogenic (★★★) | |
| SOS2 M267K | 267 | DH | Pathogenic / likely pathogenic (★★★) |
| BRAF T241K | 241 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF G464E | 464 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF L485S | 485 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF L485F | 485 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF T599I | 599 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF T599R | 599 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| HRAS T58I | 58 | Pathogenic / likely pathogenic (★★★) | |
| KRAS K5N | 5 | Pathogenic / likely pathogenic (★★★) | |
| KRAS V14I | 14 | Pathogenic / likely pathogenic (★★★) | |
| KRAS Q22R | 22 | Pathogenic / likely pathogenic (★★★) | |
| NRAS G12S | 12 | Pathogenic / likely pathogenic (★★★) | |
| NRAS G60E | 60 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 T52I | 52 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Y62D | 62 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| PTPN11 E69Q | 69 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| PTPN11 L261F | 261 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 L261H | 261 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 A461G | 461 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 A461V | 461 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 A461T | 461 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Q510P | 510 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Q510H | 510 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| RAF1 R256S | 256 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 S257P | 257 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 S259Y | 259 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 S259A | 259 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 S259T | 259 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 V263G | 263 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 K70R | 70 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| PTPN11 R265Q | 265 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| RIT1 M90V | 90 | Pathogenic / likely pathogenic (★★★) | |
| BRAF G265R | 265 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF G469E | 469 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF C532Y | 532 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF D594V | 594 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF F595L | 595 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF G596V | 596 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF V600G | 600 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| KRAS S65I | 65 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 L42R | 42 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 L42F | 42 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 N122D | 122 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 G464A | 464 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Q506P | 506 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| RAF1 T491I | 491 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| SOS1 R552S | 552 | Pathogenic / likely pathogenic (★★★) | |
| HRAS K117R | 117 | Pathogenic / likely pathogenic (★★★) | |
| NRAS I24N | 24 | Pathogenic / likely pathogenic (★★★) | |
| NRAS T50I | 50 | Pathogenic / likely pathogenic (★★★) | |
| BRAF F635L | 635 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| MAP2K1 F53S | 53 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 K57Q | 57 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 L92R | 92 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
Showing 60 of 212.
Uncertain variants prioritized for review in RASopathy
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CBL R420P | 420 | RING-type | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; R420L at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.872 |
| CBL H398R | 398 | RING-type | Conflicting reports (★) | +7: in a 3D region that tolerates change poorly (3R); H398N at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.951 |
| SOS1 M269V | 269 | DH | Conflicting reports (★) | +7: 4 other pathogenic changes within 3 positions; M269R at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.788 |
| CBL H398Y | 398 | RING-type | Conflicting reports (★) | +7: in a 3D region that tolerates change poorly (3R); H398N at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.943 |
| CBL R420G | 420 | RING-type | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; R420L at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.955 |
| SOS1 K728Q | 728 | N-terminal Ras-GEF | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; K728I at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| MAP2K1 R108Q | 108 | Protein kinase | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; R108L at the same position is pathogenic; seen in 7.5e-06 of gnomAD DNA copies; REVEL 0.728 |
| MAP2K2 V64A | 64 | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; V64F at the same position is pathogenic; seen in 7.5e-06 of gnomAD DNA copies; REVEL 0.717 | |
| MAP2K2 Y134F | 134 | Protein kinase | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; Y134C at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.704 |
| SOS1 K728T | 728 | N-terminal Ras-GEF | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; K728I at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| MAP2K1 N122H | 122 | Protein kinase | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; N122D at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.654 |
Which prediction tools work for RASopathy
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaGenome (regulatory): 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 97 out of 100
- REVEL: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 91 out of 100
- MetaSVM: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 86 out of 100
- VARITY: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 81 out of 100
- SIFT: 75 out of 100
- phyloP: 68 out of 100
- DMS / MaveDB: 61 out of 100
- AlphaGenome (splicing): 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phastCons: 55 out of 100
- Pangolin: 51 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 47 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Noonan syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the RASopathy variants (44 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the RASopathy variants (29 pathogenic / likely pathogenic).
- LEOPARD syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the RASopathy variants (16 pathogenic / likely pathogenic).
- Metachondromatosis also has ClinVar records linked to PTPN11 variants; they fall in the same places as the RASopathy variants (11 pathogenic / likely pathogenic).
- Monogenic short statue also has ClinVar records linked to PTPN11 variants; they fall in the same places as the RASopathy variants (6 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall in the same places as the RASopathy variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the RASopathy variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall in the same places as the RASopathy variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall in the same places as the RASopathy variants (10 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to BRAF variants; they fall in the same places as the RASopathy variants (9 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the RASopathy variants (14 pathogenic / likely pathogenic).
- Dilated cardiomyopathy 1NN also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the RASopathy variants (5 pathogenic / likely pathogenic).
- LEOPARD syndrome also has ClinVar records linked to RAF1 variants; they fall in the same places as the RASopathy variants (4 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to KRAS variants; they fall in the same places as the RASopathy variants (16 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to KRAS variants; they fall in the same places as the RASopathy variants (9 pathogenic / likely pathogenic).
- Autoimmune lymphoproliferative syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the RASopathy variants (5 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to KRAS variants; they fall partly in the same places as the RASopathy variants (5 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to KRAS variants; they fall in the same places as the RASopathy variants (4 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to SOS1 variants; they fall partly in the same places as the RASopathy variants (30 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to SOS1 variants; they fall partly in the same places as the RASopathy variants (9 pathogenic / likely pathogenic).
- Fibromatosis, gingival, 1 also has ClinVar records linked to SOS1 variants; they fall partly in the same places as the RASopathy variants (4 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall in the same places as the RASopathy variants (14 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall partly in the same places as the RASopathy variants (6 pathogenic / likely pathogenic).
Diseases related to RASopathy
- Noonan syndrome, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Hypertrophic cardiomyopathy, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Cardiofaciocutaneous syndrome, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Costello syndrome, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Cardio-facio-cutaneous syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Vascular malformation, also linked to BRAF, KRAS, MAP2K1 and NRAS
- Myelomonocytic leukemia, also linked to CBL, KRAS, NRAS and PTPN11
- Melanoma, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Acute myeloid leukemia, also linked to KRAS, NRAS and PTPN11
- LEOPARD syndrome, also linked to BRAF, PTPN11 and RAF1
- Colorectal cancer, also linked to BRAF, KRAS and NRAS
Frequently asked questions
Which genes have records linked to RASopathy?
This view contains 13 analyzed proteins: PTPN11, BRAF, RAF1, KRAS, SOS1 and 8 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 212 pathogenic or likely pathogenic variants, 2,235 variants of uncertain significance and 257 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 11 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 2,917 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center